iBio (IBIO) News
NASDAQ: IBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.8001-0.0009 (-0.11%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IBIO news summary
We found 4 recent headlines mentioning iBio (IBIO): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire. For price context, IBIO is down 0.11% at $0.8001. The most recent story, "iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific Conferences", was published by GlobeNewswire on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest iBio headlines
- iBio Announces New Preclinical Data Across Obesity and Cardiometabolic Portfolio at Multiple Scientific ConferencesObesityWeek 2026 data from obese non-human primates showed sustained Activin E suppression and a 2.3% vehicle-adjusted reduction in body weight from baseline with IBIO-610 at week 28.GlobeNewswire
- iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate UpdatePresented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapyGlobeNewswire
- iBio to Participate in Upcoming Investor ConferencesConference participationGlobeNewswire
- iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 TherapyIn an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide aloneGlobeNewswire